Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer.

Publication Type:

Journal Article

Source:

Journal of comparative effectiveness research, Volume 3, Issue 2, p.135-44 (2014)

Keywords:

Adolescent, Adult, Aged, Bone Marrow Transplantation, Comparative Effectiveness Research, Cord Blood Stem Cell Transplantation, Cost-Benefit Analysis, Female, Health Care Costs, Health Expenditures, Hematologic Neoplasms, Humans, Male, Middle Aged, Quality of Life, Young Adult

Abstract:

BMT CTN 1101 is a Phase III randomized controlled trial evaluating the comparative effectiveness of double unrelated umbilical cord blood (dUCB) versus HLA-haploidentical related donor bone marrow (haplo-BM) donor cell sources for blood or bone marrow transplantation (BMT) in patients with hematologic malignancies. Herein, we present the rationale, design and methods of the first cost-effectiveness analysis to be conducted alongside a BMT trial.